Sheela Upadhyaya | Life Science Advisor and Founder
Rarely Ordinary

Pre-congress workshops @ 14:00

Implementing HTA recommendations, Evidence assessment, economic modelling, and how legislation drives HTA change

Day 1 @ 16:40

Panel: Collaborations between industry and European Reference Networks (ERNs): Unlocking the Potential

Best practices and challenges in industry-ERN partnerships

Reflections of Together4Rare and lessons learned

Day 2 @ 13:45

Panel: Implications of EU HTA Joint Clinical Assessments to Patient Engagement Practices in Rare Disease

Moderator: Veronica Lopez Gousset, DrPH candidate, Harvard T.H. Chan School of Public Health

×

Veronica Lopez Gousset / Panel: Implications of EU HTA Joint Clinical Assessments to Patient Engagement Practices in Rare Disease

Veronica Lopez Gousset, DrPH candidate,
Harvard T.H. Chan School of Public Health

Veronica Lopez Gousset, MPH, has over 10 years of experience ensuring patients’ voices are represented in healthcare decision-making. She works with the patient community to better voice their needs and challenges, with health technology assessment (HTA) bodies to improve their processes for...

CloseMore

Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

×

Alexander Natz / Panel: Implications of EU HTA Joint Clinical Assessments to Patient Engagement Practices in Rare Disease

Alexander Natz, Secretary General,
EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law...

CloseMore

Sheela Upadhyaya, Life Science Advisor and Founder, Rarely Ordinary

Jan Mol, Patient Advocate, Hematon